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Abstract
Obsessive-compulsive disorder (OCD) is a psychiatric condition characterized by intrusive
and unwilling thoughts (obsessions) giving rise to anxiety. The patients feel obliged to per-
form a behavior (compulsions) induced by the obsessions. The World Health Organization
ranks OCD as one of the 10 most disabling medical conditions. In the class of Anxiety
Disorders, OCD is a pathology that shows an hereditary component. Consequently, an on-
line resource collecting and integrating scientific discoveries and genetic evidence about
OCD would be helpful to improve the current knowledge on this disorder. We have de-
veloped a manually curated database, OCD Database (OCDB), collecting the relations be-
tween candidate genes in OCD, microRNAs (miRNAs) involved in the pathophysiology of
OCD and drugs used in its treatments. We have screened articles from PubMed and
MEDLINE. For each gene, the bibliographic references with a brief description of the gene
and the experimental conditions are shown. The database also lists the polymorphisms
within genes and its chromosomal regions. OCDB data is enriched with both validated and
predicted miRNA-target and drug-target information. The transcription factors regulations,
which are also included, are taken from David and TransmiR. Moreover, a scoring function
ranks the relevance of data in the OCDB context. The database is also integrated with the
main online resources (PubMed, Entrez-gene, HGNC, dbSNP, DrugBank, miRBase,
PubChem, Kegg, Disease-ontology and ChEBI). The web interface has been developed
using phpMyAdmin and Bootstrap software. This allows (i) to browse data by category
and (ii) to navigate in the database by searching genes, miRNAs, drugs, SNPs, regions,
drug targets and articles. The data can be exported in textual format as well as the whole
database in.sql or tabular format. OCDB is an essential resource to support genome-wide
analysis, genetic and pharmacological studies. It also facilitates the evaluation of genetic
data in OCD and the detection of alternative treatments.
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Introduction
Obsessive-compulsive disorder (OCD) is a neurological dis-
ease characterized and recognized by intrusive, persistent
and unwanted thoughts (obsessions) and repetitive behavior
(compulsions). It is a highly debilitating disease because the
patients cannot live a normal existence, in fact they have to
repeat the same actions or think the same thoughts to obtain
a temporary relief (1, 2). The recurrent phenotypes are sym-
metry/ordering, hoarding, contamination/cleaning, and ob-
sessions/checking (1) Another phenotype is the ‘pure
obsessional’ with sexual, somatic, religious obsessions and
mental rituals (2). In some instances, this behavior can in-
clude trying to avoid to walk on lines of sidewalks and
floors; washing hands or face time after time; sorting
objects by size; performing precise thoughts or prayers be-
fore entering in a place. OCD affects both children and
adults (3, 4). In many cases, the first symptoms appear in
childhood and early adolescence. Most of the patients are
under the age of 20 (5), and in particular, 21% of the cases
are children around the age of 10 years (6). Historically, the
guidelines of International Classification of Diseases, 10th
revision (ICD-10) and Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition, Text Revision (DSM IV TR)
classified OCD into the anxiety disorders class (7, 8). The
anxiety disorders were a broad and heterogeneous group of
disorders including acute stress disorder, agoraphobia and
many others (8). Recently, the American Psychiatric
Association has published an upgrade in which OCD ap-
pears in a separate category called Obsessive-compulsive
and related disorders (OCRDs) (9, 10). Thus, there is a
growing attention for this disorder, with changes in the
diagnostic criteria together with significant clinical implica-
tions (11). The World Health Organization, accordingly,
ranks OCD as one of the 10 most disabling medical condi-
tions worldwide (12).
OCD was described, for the first time, around a century
ago by psychologist Pierre Janet (13). Nowadays, we know
that OCD has a genetic component for its origin. The first
fundamental OCD genome-wide linkage scan study was
conducted by Hanna et al. (14) in which they identified re-
gions in chromosomes 2, 9 and 16. Several other similar
studies analysed the genetic linkage between 9p24 and
OCD, and moreover, a few candidate genes have been
identified (15, 16).
Few studies have highlighted the heritability of such a
disease. In particular, the early onset of OCD (17) and the
ordering/symmetry symptoms of OCD (18) are frequently
heritable. A high risk of developing OCD or some symp-
toms in first-degree relatives has also been reported (19–21).
We know that in the 9p24 chromosomal region there is a
candidate gene associated with OCD, SLC1A1/EAAC1 (22,
23), which encodes for the neuronal/epithelial high affinity
glutamate transporter (23). SLC1A1 is expressed in some
functional areas of the brain (24) and is implicated in OCD
in the cortico-strial-thalamic-cortical circuits (CSTC) (25).
Much evidence shows an altered glutamate neurotransmis-
sion within CTSC circuits in the pathophysiology of
OCD (25). The neuronal glutamate transporter gene
(SLC1A1) is mainly expressed within CSTC circuits (24).
To date, researchers have identified many candidate
genes as well as some regions of the genome that might
include disease genes (26). Such genes include SLC6A4 (27,
28), HTR2A (29, 30), HTR2C (29), NTRK3 (31) and
SLITRK1 (32).
The nervous system requires an accurate regulation at
all control levels. The post-transcriptional regulation of
genes has a fundamental role in the pathophysiology of
neurologic diseases (33); and for this reason, a great deal
of research has been devoted to microRNAs (miRNAs)
(34), which constitute a small class of non-coding RNAs.
These molecules are 22 nucleotides (nt) long and are
involved in several processes such as gene expression regu-
lation, translational repression, mRNAs degradation and
RNA silencing (35, 36). In addition, they also regulate
>30% of all protein-coding genes (36). Muin˜os-Gimeno et
al. (37) found a role of the neurotrophin-3 receptor gene
(NTRK3) in the pathophysiology of anxiety disorders. In
fact, such a gene has a high variation in the miRNA recog-
nition element (MRE) of miR-485-3p, which is one of the
most important miRNA associated to OCD (37). Finally,
guidelines to treat OCD include both a psychotherapy
called cognitive behavior therapy (CBT) and a pharmaco-
logical therapy. CBT is often not enough in ‘pure obses-
sional’ because patients have to control many rituals (38).
The World Federation of Societies of Biological Psychiatry
published the guidelines for the pharmacological treatment
of OCD (39). Positive evidence is associated with the usage
selective serotonin reuptake inhibitors (SSRIs) such as flu-
voxamine, fluoxetine, escitalopram, paroxetine and sertra-
line, and for tricyclic antidepressant (TCA) such as
clomipramine (39).
Despite the efficacy of some approved drugs (such as
SSRIs and clomipramine), 40–60% of patients do not
show any significant improvements (40, 41).
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Consequently, alternative treatments and new drugs in
combination with SSRIs or TCA, might become necessary.
A study based on agomelatine augmentation to escitalo-
pram therapy shows promising results (42). In fact, agome-
latine is a 5-HT2c receptor antagonist (43) that determines
a therapeutic response with total remission of the symp-
toms and with a Yale-Brown Obsessive-Compulsive Scale
(Y-BOCS) (44) score of 5 (initial Y-BOCS score was of 33)
(42).
In general, Y-BOCS evaluates the severity of OCD
symptoms using a score ranging from 0 and 40. In fact,
OCD scores can be 0–7, sub-clinical; 8–15, mild; 16–23,
moderate; 24–31, severe; 32–40, extreme (44).
In this work, we propose the first manually curated
database, named OCD Database (OCDB), which collects
genomic evidence related to OCD from literature. OCDB
lists information about genes and chromosomal regions
involved in the disease, which include transcription factors,
regulations, polymorphisms, predicted and validated
miRNAs, drugs targeting such genes, pathways in which
genes enter, drugs currently used to treat OCD as well as
the related pathologies. Moreover, we have defined a scor-
ing method to assess the relevance to OCD of each item in
OCDB. OCDB is equipped with a web interface in which
users can search and browse genes, articles, miRNAs,
Single-nucleotide polymorphisms (SNPs), drugs, drug tar-
gets and chromosomal regions related to OCD. OCDB re-
turns the searched entities with all the information
connected to them. Users can save the results in.html
and.txt formats. The entire database is also provided in.sql
and table formats. OCDB is available online at: http://
alpha.dmi.unict.it/ocdb/.
Materials and methods
OCDB is a relational database implemented in MySQL
with a web interface that was developed using
phpMyAdmin and Bootstrap software. The database is
hosted at the University of Catania and is accessible at
http://alpha.dmi.unict.it/ocdb/
Figure 1 reports the architecture of OCDB. It describes
the data extracted from literature and other external re-
sources, how they are linked and the users’ assess modes.
The manually curated data in OCDB
The data stored in OCDB database has been collected
from PubMed (45) and Medical Literature Analysis and
Retrieval System Online (MEDLINE), updated until
March 2015. By querying the earlier databases, we have
done a comprehensive search concerning ‘OCD and genes,
miRNAs, SNPs, drugs, drug therapy and treatments’,
‘OCD and genes’ and ‘OCD and genetic association stud-
ies’. This yield an outcome of 11 129 articles. Next, we
have excluded the articles focusing on the psychological
and epidemiological aspects, studies not in human and art-
icles without an English abstract or completely lacking an
available abstract. Finally, we obtained 1076 suitable art-
icles for further processing.
A custum Python script, utilizing the Entrez API, helped
us to retrieve data from National Center for Biotechnology
Information (NCBI) resources (46). Through this, we ob-
tained information about the articles (such as pmid, title,
authors, journal, publication year) as well as gene symbols,
SNPs and drug names, which were retrieved from
Drugbank. In addition, OCDB includes manually curated
data extracted from the articles. These include miRNAs
names, experimental details (number of the samples, soft-
ware and technologies used), notes about the scientific re-
sults, genomic regions, the role of the genes in the
pathologies in comorbidity with OCD, the pharmaco-
dynamics and pharmacological actions (if known) and the
effects of the drugs and endogenous molecules on OCD.
The data available in the current version of the database
cover 536 publications reporting on 180 polymorphisms in
153 genes and 16 miRNAs, 148 regions, 25 related pathol-
ogies as well as 48 drugs.
OCDB external resources.
To enrich its content, OCDB provides links to several ex-
ternal resources. These include (i) Entrez-gene (v. 2015-04-
05)(GRCh38) (46) and HUGO Gene Nomenclature
Committee (HGNC) (v.2.0.0 2015-01-19)(GRCh38) (47)
to have official gene names and gene_ids; (ii) Single
Nucleotide Polymorphism database (dbSNP) Build 143
(48) to retrieve the rs# numbers of SNPs; (iii) DrugBank
(v.4.2) (49) to have information about drugs, such as
pharmaceutical categories and therapy indications; (vi)
miRBase(v.21) (50) and Pubchem (v. 2015-04-9) (51) to
have more research material linked with miRNAs and en-
dogenous molecules, respectively. In addition, transcrip-
tion factors for genes and miRNAs are obtained from
DAVID (v. 6.7) (52, 53) and TransmiR (v.1.2) (54). Genes
have been associated to their respective pathways by using
Kegg-Pathway (v.2015-04-06) (55, 56). Diseases and drugs
have been linked to the disease-ontology (v. 2015-04-18)
(57) and ChEBI ontology (v. 2015-04-01) (58),
respectively.
Data prediction.
To help inferring new venues in the treatments and in the
underlying genetics, miRNA-gene and drug-targeting pre-
dictions have been integrated within OCDB.
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Notably, miRNA predictions have been obtained by
using TargetScan (59), miRTarBase (60) and miRanda (61)
while drug predictions have been obtained from DrugBank
(49) and by using Domain Tuned-Hybrid (DT-Hybrid)
algorithm (62). Predictions from DrugBank (49) are distin-
guished among Targets, Enzymes, Transporters and
Carriers.
More precisely, the DT-Hybrid algorithm implements a
functional framework, based on a recommendation tech-
nique, for the in silico prediction of drug-target interactions.
It plugs into the network-based inference model specific do-
main knowledge such as the similarity among drugs and tar-
gets. The algorithm produces a set of new associations from
which novel biological insight can be discovered. For each
drug-predicted target pair, the algorithm also associates a
score measuring the degree of certainty of the interaction.
Such a value depends strongly on the neighborhoods of the
drug and target, and their similarity to the neighbors. The
range of each score is (0, 3), where zero indicates the ab-
sence of interaction, and three indicates a reliable
interaction.
Scoring method.
We defined a score method to measure the relevance (spe-
cificity) of the information in our system to OCD. The con-
cept of relevance of an item A (gene, miRNA, drug, SNP,
region) to the pathology OCD is defined through a triplet
of values normalized by z-scores (63):
• w1: the number of articles in OCDB containing A and
the association with the pathology OCD.
• w2: the number of relations (A, B) in the database. If A
is:
• gene; then B is a miRNA or drug cited in the same art-
icle, a SNP or a region in A.
• miRNA; then B is a gene or miRNA cited in the same
article, a SNP or region in A.
• drug; then B is a gene, miRNA, region or SNP cited in
the same article.
• SNP: then B is a gene, miRNA, region or drug cited in
the same article.
• Region; then B is a gene, miRNA, SNP or drug cited in
the same article.
Figure 1. OCDB architecture.
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• w3: the number of articles in the database reporting the
association among A and some other pathology, men-
tioned in the articles, related to OCD.
The score of A is the linear combination of w1, w2 and
w3 normalized by z-score. The ratio behind this ranking is
that OCDB does not highlight the biological importance of
the item itself or the research involving it; but it weights
how in our manually curated resource the item is specific-
ally associated to OCD (w1) and to close other related
pathologies (w3), and as much information about this item
and its ‘neighbors’ (i.e. its relations) can be extracted from
OCDB (w2). Consequently, the articles are not classified
but instead the items they contain. Finally, the scores are
also presented as classes according to the quartile they be-
long; the quartiles are represented by colors and numbers
(red-1, yellow-2, green-3, light blue-4).
Data interface
The main OCDB interface modules are Search, Advanced
Search, Browse and Download/update. These allow (i) to
browse the data; (ii) to navigate in the database by search-
ing genes, miRNAs, drugs, articles, SNPs, regions and drug
target; and (iii) to download and upload the data.
For each search type, OCDB guides the writing to avoid
misspelled inputs. There are two levels of input control
checking, a client side and a server side. The input nomen-
clature is based on the official scientific standard com-
monly used by online databases. The statistics on the
OCDB data are reported together with a brief documenta-
tion on the usage of the database content.
Search and Advanced Search.
The Search section allows users to query the system by
genes, miRNAs and drugs. In the Advanced Search, users
can query OCDB by article, SNPs, regions and drug target.
The drug target section points to genes that are targets of
drugs used in the treatments.
Genes are specified by using the nomenclature of
HGNC (49) and Entrez-gene by NCBI (46). The nomencla-
ture of miRNAs refers to the ones used in miRBase (50).
Drugs are inserted by their names as reported in DrugBank
(49). Studies can be retrieved through a full text search by
entering the title, the author names or the year of publica-
tion. SNPs should be inserted by rs# number corresponding
to the nomenclature in dbSNP (48). If the user searches by
region, the nomenclature references to cytogenetic
standards.
Results are organized in the following cards (see
Figure 2). We refer searched genes, miRNAs, drugs, art-
icles, SNPs or genomic regions to as items.
• Info: Info gives nomenclature information, links to the
web resources and allows downloading a full card of the
searched item. If the item is an article, it shows details of
the publication (i.e. the title, the author names, the jour-
nal, the publication year, note describing the results, if
available details on the used techniques, sample and soft-
ware) together with a link to PubMed (45). When the
searched item is a gene, OCDB reports entrez_id, gene
names, aliases, encodes and links to HGNC and NCBI.
If the item is a miRNA, the system shows miRBase access
number together with a link to the resource. If the item is
a drug, OCDB reports the drug names, the drug pharma-
codynamics and links to DrugBank and ChEBI. If the
item is a SNP, it shows names and NCBI link. Finally, if
it is a region, its name is given.
• Articles: Articles show references to articles mentioning
the item (the title, the author names, the journal, the
publication year, note describing the results) and the
PMID linking to PubMed (45).
• Genes: Genes show the genes, which are targets of
the searched miRNA or drug, containing the SNPs or the
genes in the searched chromosomal region. It reports the
links to HGNC and NCBI, alias, encodes and the role of
genes (if the genes are retrieved from articles or if the
genes are validated and/or predicted miRNA’s target).
• Drugs: If the item is a gene, shows the drugs that have
the gene as a target, linked to DrugBank 4.2 (49) to-
gether with its type and a description, if available. The
data are extracted from DrugBank (49) (targets, trans-
porters and enzymes) or computed by the DT-Hybrid al-
gorithm (62). For all other items, this section reports
details on drugs (if any) that in OCDB articles have been
associated with the searched item. Details are the gene
names linked to Entrez by NCBI (46), endogenous mol-
ecules involved and the actions that the drugs has on the
targets. There may also be information about the thera-
peutically indications, pharmacodynamics, pharmaco-
logical action and eventually the effects of drug on OCD
extracted from the indexed articles.
• Endogenous molecules: if the item is a drug, it shows the
endogenous molecules and genes on which the drug may
have effect and their description. The effect is specified in
‘action’. The name of molecules is linked to PubChem (51).
• miRNAs: miRNAs show the miRNA-name linked to
miRBase (50). If the item is a gene, it reported the predic-
tion of miRNAs targeting such a gene made by
TargetScan (59), miRanda (61) and mirTarBase (60).
• SNPs: SNPs show the SNPs present in the item. The SNP
name is linked to dbSNP (48). If the item is not a gene,
OCDB shows also the gene name linked to Entrez-gene
card (46) or the miRNA access number containing the
SNP.
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• Regions: Regions give the chromosomal location of the
selected item (i.e. a gene, miRNA, SNP); When the item
is a drug, region yields the chromosomal location of tar-
geted genes; When the item is a region, the list of gens,
SNPs and miRNAs falling in such region are given to-
gether with the list of article citing such a region.
• Pathologies: Pathologies show pathologies in which the
item is associated with OCD or with any other pathology
related to OCD (such as social phobia or schizophrenia
in comorbidity with OCD), which has been reported in
literature. Each pathology is associated to Disease-ontol-
ogy code (57).
• Transciption factors: By using DAVID (52, 53), we
have obtained transcription factors related to our
gene set. For miRNAs, we retrieved from TransmiR
(54) the genes-miRNAs regulations. Note the
Figure 2. OCDB Interface. (A) General information about ADARO2A, links to HGCN and NCBI and the gene card download option. (B) Information
about the articles mentioning results on ADARO2A are listed. (C) Drugs targeting ADARO2A taken from literature. The page reports also drugs target-
ing (not shown here) predicted by DT-Hybrid algorithm and taken from DrugBank. Other OCDB interface sections are not shown. (D) miRNAs men-
tioned in the articles targeting ADARO2A are given. Validated and predicted miRNAs from online databases targeting ADARO2A are listed.
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update gene name of transcription is linked to Entrez as
well as the gene-miRNAs regulation is linked to
miRBase.
• Pathways: Pathways gives the list of pathways in which
genes enter.
Users can visualize all details and relative relations with
genetic elements present in the database of each item re-
ported in the results cards by clicking ‘see more’. This is
useful to navigate inside the database.
Browse.
This interface lists all genes, drugs, miRNAs, studies, SNPs
and regions in OCDB. For all items, with the exception of
studies, the relevance to the OCD is returned.
More precisely, when browsing for ‘Gene’, OCDB lists
the gene name, its aliases and if it is a target of drugs used
in OCD treatments. This section contains a tab to list all
genes per chromosome. ‘Drug’ lists all names of drugs clin-
ically used in OCD or related pathologies as reported in
the articles in the OCDB. By clicking in ‘miRNA’ users can
see the name and a description of the role of the miRNAs
in the pathology. This is one of the sentences extracted
from related articles. ‘Studies’ lists the year of publications,
the title and PubMed-id. SNPs and Region-ids are listed in
two distinct sections. ‘Regions’ are associated with
markers, when available. In all browsing sections by click-
ing on ‘see more’, users can visualize the details and the
relative relations with genetic elements present in OCDB.
The users can visualize the results in alphanumeric
order with respect to any of the listed attributes.
Moreover, a score representing the relevance of the gene,
miRNA, drug, SNP or region with respect to the disease is
given. For the earlier elements, users can order results in
descending or ascending order by using such attribute
scores.
Statistics.
Statistics section reports the amount of data by category,
with particular attention to the number of interactions by
category. We refer to Figure 3 for the OCDB statistics. The
number concerning the manually curated data are the fol-
lowing: 536 articles, 153 genes, 16 miRNAs, 180 SNPs, 48
drugs and 148 chromosomal locations. The data enriched
by using external sources and predictions software are the
following: 143 therapeutic indications from DrugBank, 50
pathways, 8701 gene and 566 miRNA trascription factor
regulations, 37 435 MirTarBase predictions, 91 062
miRanda predictions, 146 125 TargetScan predictions, 59
218 DT-Hybrid predictions and 2276 DrugBank targeting
relations.
Documentation.
The documentation section shows general information
about the aim and the structure of OCDB, and a descrip-
tion of OCD.
The database is free for all users, and we distribute the
data under a Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 License.
Data maintenance
OCDB will be continuously updated, through manual
screenings of new publications on PubMed (45) together
with automatic procedures alerting new publications.
Therefore, again the combination of manual and auto-
matic procedures will extract and evaluate genetic infor-
mation. After these steps OCDB will be updated.
In addition, researchers can suggest new or missing
findings to be inserted in the database by contacting au-
thors by email. Our contact information is reported in the
‘Contact’ page.
Data distribution
Download/upload.
The whole database can be dumped, together with the
SQL scripts, as a compressed archive.gz. Search results (i.e.
by gene, miRNA, drug, article, SNP and region) can be
downloaded in.txt or HTML format through the section
‘Info’. Data are also available for download in tabular
format.
Figure 3. Statistics on (A) the manually curated data and (B) data
obtained by using external sources and predictions software.
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Utility and discussion
Through the literature screening several inferences regard-
ing genes and treatments about OCD may come to light.
Until present day, most studies have been conducted on the
same genes and the same drugs related to OCD. Some
drugs used for the treatment of obsessions do not have a
great efficacy in the treatment of OCD and are often them-
selves cause of the disease (i.e. Risperidone). According to
the fact that in the worldwide population OCD is more
common than it is really perceived (with a prevalence of 2–
3%) (12), our system OCDB can help to give a comprehen-
sive view about the main genes, drugs or miRNAs involved
in the pathology. By querying OCDB, researchers can
make new hypothesis and infer novel knowledge.
Case study 1
DRD2 (D(2) dopamine receptor) and ADORA2A (adeno-
sine A2a receptor) a correlation among OCD caffeine,
nicotine and SSRIs
Prior knowledge.
DRD2 (D(2) dopamine receptor) is involved in OCD (64),
and ADORA2A (adenosine A2a receptor) is a validated
target site of hsa-miR339 associated with panic disorder
(65). Caffeine can produce anxiogenic effect antagonizing
adenosine at A(2A) receptors, which are colocalized with
dopamine receptors in the brain (66). In a healthy person
the effects are irrelevant or can be different if associated
with polymorphisms in the ADORA2A gene (66).
How to use OCDB.
Through OCDB we may know which are the drugs or mol-
ecules active on ADORA2A and DRD2. This can be easily
obtained by querying OCDB through the following path:
Search ADORA2A (the same applies for DRD2), then
click on ‘Drugs’ in the tab-bar menu, browse prediction
data in the section ‘Drug-targets (DT-Hybrid)’ in OCDB.
The results indicated that the molecules active on that
genes are caffeine and nicotine while one of the drugs is
fluvoxamine.
Posterior knowledge.
Pasquini et al. (67) present a case of OCD resistant to con-
ventional treatments, which improved following nicotine
augmentation administered as 4 mg chewing gum. Tizabi
et al. (69) show as nicotine attenuates some symptoms of
compulsive checking in a rat model of OCD.
Conclusion.
It could be interesting to investigate what effects the stimu-
lation of these receptors produce in patients with
anxiogenic background such as OCD or panic disorder as
well as the simultaneous use of caffeine and nicotine with
fluvoxamine.
Case study 2
miRNAs prediction reporting on DRD2 and ADORA2A.
Prior knowledge.
It is known that ADORA2A (adenosine A2a receptor) is a
validated target site of hsa-miR339 associated with panic
disorder (65).
How to use OCDB.
OCDB stores also predicted miRNAs on ADORA2A (see
Table 1). This may be visualized through the following
path: Search ADORA2A, click ‘miRNAs’ in tab-bar menu
of such gene and use prediction data in the section
‘miRNA target predictions (miRanda)’. The same must be
done for DRD2. We have used the prediction data from
miRanda (61), but there are also predictions from
TargetScan (59) and MirTarBase (60).
Posterior knowledge.
Among these, several miRNAs have been validated and
predicted to be involved in OCD and panic disorder. For
instance, miR-488 is a repressor of POMC (proopiomela-
nocortin) (65), miR-485-5p is associated with hoarding
subtype of OCD (37), miR-204 and miR-211 are associ-
ated with ALAD (aminolevulinatedehydratase) in social
phobia (69) and miR-339 is associated with panic disorder
(65). In addition to having this data and using online re-
sources, we have conducted a functional enrichment using
WebGestalt (70) to individuate in which biological func-
tions DRD2 and ADORA2A are involved (see Table 1).
Conclusion.
The studies about the relation between miRNAs and OCD
or some anxiety disorders are very recent. Only for few
miRNAs, the function on this gene is known. Hence, the
remaining predicted miRNAs could be interesting for fur-
ther investigations (see Table 1).
Case study 3
Polymorphisms in gene target, as in SLC6A, could influ-
ence treatments and the efficacy of drug therapies.
Prior knowledge.
Several OCD patients do not respond to conventional
treatment. In OCD treatment, the main drug-targets are (i)
SERT1 or 5-HTT solute carrier family 6 encoded by
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SLC6A4, (ii) 5-hydroxytryptamine (serotonin) receptor
2C- G protein-coupled encoded by HTR2C and (iii) dopa-
mine transporter encoded by SLC6A3.
How to use OCDB.
OCDB contains SNPs within genes, miRNAs, miRNA-
targets and drug-targets. The SNPs and the predicted drugs
in SLC6A4 can be obtained in OCDB through the follow-
ing path: Search SLC6A4, click ‘SNP’ in tab-bar menu and
browse the main SNPs associated with OCD in SLC6A4;
also click ‘Drug’ in tab-bar menu and browse prediction
data in the section ‘Drug-targets (DT-Hybrid). The pre-
dicted drugs are phentermine, pregabalin, doxycycline,
venlafaxine, amitriptyline and tolcapone.
Conclusion.
An SNP within a drug-target could influence treatment and
the efficacy of drug therapy. Studying predicted drug
targets, researchers could make hypothesis on new drug
combination for treatments.
Case study 4
Finding a validation between oxidative stress and anxiety
disorder.
Prior knowledge.
Another point of investigation involves the oxidative stress.
GSTP1 (glutathione S-transferase pi 1) is a target of clo-
mipramine, a TCAs (71).
How to use OCDB.
We have interrogated OCDB to know which are other
gene targets of Clomipramine. This can be easily obtained
by querying OCDB through the following path: Search in
drug section Clomipramine, by clicking ‘Genes’ in tab-bar
menu. The list shows GSTP1, HTR2A, HTR2B, HTR2C,
Table 1. Association studies by using OCDBa
Genes Predicted drugs
(DT-Hybrid)
Predicted miRNAs
(miRanda)
Description Functional enrichment References
DRD2a Caffeine,
Nicotine,
Fluvoxamine
miR-140-5p, miR-9, miR-
150, miR-185, miR-190,
miR-34c-5p, miR-377,
miR-379, miR-330-5p,
miR-326, miR-346, miR-
449a, miR-181d, miR-539,
miR-449b, miR-876-5p,
miR-190b
No association re-
ported in literature
Synaptic transmission, multicellu-
lar organismal signaling, trans-
mission of nerve impulse, system
process, neurological system
process, neuron–neuron synap-
tic, behavior, regulation of syn-
aptic transmission, regulation of
transmission of nerve, regulation
of neurological system, negative
regulation of synaptic transmis-
sion, learning or memory, cell
communication, startle re-
sponse, response to drug, cat-
echolamine transport, negative
regulation of transmission of
nerve impulse, drug binding,
neurotransmitter receptor
activity
Billett et al. (64)
ADORA2Aa Caffeine,
Nicotine,
Fluvoxamine
miR-182; miR-204, miR-
211, miR-214, miR-216a,
miR-134, miR-149, miR-
150, miR-34c-5p, miR-
378, miR-383, miR-330-
5p, miR-328, miR-342-3p,
miR-326, miR-339-5p,
miR-422a, miR-485-5p,
miR-488, miR-494, miR-
542-3p, miR-543, miR-34a
miR-488 is a repressor
of POMCc
miR-339 associated
with panic disorderc
miR-485-5p is associ-
ated with hoarding
subtype of OCDd
miR-204 and miR-211
are associated with
ALAD in social
phobiae
Neurological system process, neu-
ron–neuron synaptic, behavior,
regulation of synaptic transmis-
sion, regulation of system pro-
cess, regulation of transmission
of nerve impulse, regulation of
transmission of nerve impulse,
signaling, startle response, re-
sponse to drug, catecholamine
transport, trans-membrane sig-
naling receptor activity
Billett et al. (64)
Muin˜os-Gimeno
et al. (65)
Muin˜os-Gimeno
et al. (37)
Donner et al.
(69)
aStarting from a gene involved in OCD, DRD2 and ADORA2A, which is a validated target of hsa-miR339 associated with panic disorder, we found predicted
drugs and miRNAs for these genes. A functional enrichment is also reported. bRef. (64). cRef. (65). dRef. (36). eRef. (69).
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SLC6A2 and SLC6A4. Then, we ask if each gene has gluta-
thione as a predicted drug. Thus, by searching for each
gene and clicking ‘Drugs’ in tab-bar menu, in the section
‘Drug target predictions (DT-Hydrid)’ we discovered that
some of these genes are targets of semisynthetic molecules
like glutathione: glutathione sulfonic acid, S-(P-nitroben-
zyl)-glutathione and S-hexylglutathione, (HTR2B,
HTR2C, SLC6A2, SLC6A4).
Posterior knowledge.
There is an interest on the oxidative stress in the etiology
and progression and prevention of psychiatric disorders
(72). Strong emotions or emotional stress can lead to men-
tal states of depression or anxiety, with substantial conse-
quences on lifestyle and health (73). During drug therapy,
some miRNAs could change their concentration and thus
influence the expression of their target. For example in a
study on mice, miR-16 targets SERT. After treatment with
fluoxetine, i.e. a SSRI (selective serotonin reuptake inhibi-
tors), the miR-16 level increased with a reduced SERT ex-
pression. This is a case in which miRNAs play a synergistic
role in therapy (74).
Conclusion.
The oxidative stress could alter and disrupt the neural cir-
cuits, which might be the implications of the use of gluta-
thione in the treatment of OCD. In addition, miRNAs
could have unexpected implications in this pathology, be-
cause miRNAs regulate multiple pathways in the brain in
which minimal changes in gene expression or regulation
could be fatal (76).
Conclusion
OCDB is the first online resource containing genomic in-
formation related to OCD. We have collected the informa-
tion from bibliography on PubMed. We have enriched the
database with prediction analysis of miRNAs and drugs.
Users can browse the information in the database by cat-
egory (genes, articles, miRNAs, drugs, chromosomal re-
gion, SNP and drug target) or starting by searching a
specific element (e.g. gene) and retrieve all connected infor-
mation (targeting miRNAs, drugs and so on). By looking
at OCDB, researchers can create a possible panel of gen-
omic elements involved in the pathophysiology of disease.
Finally, OCDB can provide the basis for further hypothesis
and application of outcomes in the medium to long term.
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